Illumina (ILMN) Expected to Release Quarterly Earnings on Thursday

by · The Markets Daily

Illumina (NASDAQ:ILMN – Get Free Report) is expected to be issuing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to post earnings of $1.36 per share and revenue of $1.15 billion for the quarter. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the company earned $1.19 EPS. The firm’s revenue for the quarter was up 9.4% on a year-over-year basis. On average, analysts expect Illumina to post $5.36 EPS for the current fiscal year and $6.12 EPS for the next fiscal year.

Illumina Stock Up 3.1%

NASDAQ ILMN opened at $279.47 on Wednesday. The business has a 50 day simple moving average of $245.13 and a 200 day simple moving average of $174.27. Illumina has a one year low of $94.00 and a one year high of $309.35.

Insider Transactions at Illumina

In other Illumina news, Director Keith Meister sold 457,858 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,061,850 shares of company stock valued at $436,479,102 in the last 90 days. 2.90% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

ILMN has been the topic of several recent analyst reports. Leerink Partners boosted their price target on Illumina from $220.00 to $300.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. Stifel Nicolaus raised their price objective on shares of Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Piper Sandler boosted their target price on shares of Illumina from $225.00 to $305.00 and gave the company an “overweight” rating in a research report on Monday, September 28th. Barclays boosted their target price on shares of Illumina from $160.00 to $200.00 and gave the company an “underweight” rating in a research report on Wednesday, October 7th. Finally, Royal Bank Of Canada raised their price target on shares of Illumina from $230.00 to $310.00 and gave the stock an “outperform” rating in a report on Monday, October 5th. Ten investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $234.41.

Get Our Latest Stock Report on Illumina

About Illumina

(Get Free Report)

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.

Read More